Abstract
This article reports the design, synthesis, and evaluation of a novel class of molecules of intermediate size (approximately 7000 Da), which possess both the targeting and effector functions of antibodies. These compounds—called synthetic antibody mimics targeting prostate cancer (SyAM-Ps)—bind simultaneously to prostate-specific membrane antigen and Fc gamma receptor I, thus eliciting highly selective cancer cell phagocytosis. SyAMs have the potential to combine the advantages of both small-molecule and biologic therapies, and may address many drawbacks associated with available treatments for cancer and other diseases.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies / metabolism*
-
Antigens, Surface / chemistry
-
Antigens, Surface / metabolism
-
Biomimetic Materials / chemical synthesis*
-
Biomimetic Materials / metabolism
-
Biomimetic Materials / pharmacology*
-
Cell Line, Tumor
-
Chemistry Techniques, Synthetic
-
Drug Design*
-
Glutamate Carboxypeptidase II / chemistry
-
Glutamate Carboxypeptidase II / metabolism
-
Humans
-
Molecular Docking Simulation
-
Molecular Weight
-
Phagocytosis / drug effects
-
Protein Conformation
-
Receptors, IgG / metabolism
Substances
-
Antibodies
-
Antigens, Surface
-
Receptors, IgG
-
FOLH1 protein, human
-
Glutamate Carboxypeptidase II